<!DOCTYPE html PUBLIC >
<html>

  <head>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
	<link rel="stylesheet" type="text/css" href="livesite_css\defaults.css">
    <link rel="stylesheet" type="text/css" href="livesite_css\projectroot.css">
    <link rel="stylesheet" type="text/css" href="livesite_css\style.css">
    <title>
      Step 2: Select Agent
    </title>
    <script src="js\jquery.js">
    </script>
    <script src="js\jquery_ui\jquery-ui.js">
    </script>
    <script src="js\mCustomScrollbar\jquery.mCustomScrollbar.js">
    </script>
    <script src="js\menu.js">
    </script>
    <script src="js\custom-accordion.js">
    </script>
    <script src="js\jquery.cookie.js"></script>
    <script src="js\text-resize.js"></script>
	<script src="js\jquery.colorbox.js"></script>
	<script src="js\colorbox-script.js"></script>
  </head>

  <body>
    <div class="page" id="page">
      <div class="page-width">
        <div id="header">
          <div class="header clearfix">
            <div class="hd-wr clearfix">
              <div class="fl logo">

                <a href="index.html">

                  <img alt="Project Root Logo" height="63" src="img/logo.png" width="332">
                </a>

              </div>
              <div class="fr">
                <div class="search">
                  &nbsp;
                </div>
    
                <div class="txt-rsg fr">
                  <a class="small " href="javascript:void(0);">
                    A
                  </a>

                  <a class="med active" href="javascript:void(0);">
                    A
                  </a>

                  <a class="large" href="javascript:void(0);">
                    A
                  </a>
                </div>
              </div>
            </div>
          </div>
          <div id="navigation" class="horizontal">
            <div id="block-system-main-menu" class="block block-system block-menu menu-dropdown block-none clearfix">
              <div class="inner tb-terminal">
                <div class="top">
                  <div class="top-inset-1 tb-terminal">
                    <div class="top-inset-2 tb-terminal">
                    </div>
                  </div>
                </div>
                <div class="middle tb-terminal">
                  <div class="content">
                    <ul class="menu pulldown-processed menu-dropdown-js-enabled pulldown">
                      <li class="first leaf level-1 menu-link-2316">
                        <a href="index.html" title="">
                          Home
                        </a>
                      </li>
                      <li class="expanded level-1 menu-link-2971">
                        <a title="" class="menu-dropdown-with-ul">
                          About Rethink Opioids
                          <span class="more-indicator">
                            »
                          </span>
                        </a>

                        <ul class="menu" style="visibility: hidden; display: none;">
                          <li class="first leaf level-2 menu-link-2326">
                            <a href="what-is-project-root.html" title="">
                              What Is Rethink Opioids?
                            </a>
                          </li>
                          <li class="last leaf level-2 menu-link-2331">
                            <a href="steering-committee.html">
                              Meet the Steering Committee
                            </a>
                          </li>
                        </ul>
                      </li>
                      <li class="expanded level-1 menu-link-2976">
                        <a title="" class="menu-dropdown-with-ul">
                          Why Rethink Opioids?
                          <span class="more-indicator">
                            »
                          </span>
                        </a>

                        <ul class="menu" style="visibility: hidden; display: none;">
                          <li class="first collapsed level-2 menu-link-2336">
                            <a href="why-rethink-opioids.html">
                              Why We Must Rethink Opioids
                            </a>
                          </li>
                          <li class="leaf level-2 menu-link-2341">
                            <a href="prescription-opioid-abuse.html">
                              The Problem of Prescription Opioid Abuse
                            </a>
                          </li>
                          <li class="last leaf level-2 menu-link-2346">
                            <a href="concerns-of-health-care-professionals.html">
                              Concerns of Health Care Professionals and Patients
                            </a>
                          </li>
                        </ul>
                      </li>
                      <li class="expanded active-trail level-1 menu-link-2981">
                        <a title="" class="menu-dropdown-with-ul">
                          Practical Approaches
                          <span class="more-indicator">
                            »
                          </span>
                        </a>

                        <ul class="menu" style="display: none; visibility: hidden;">
                          <li class="first leaf level-2 menu-link-2351">
                            <a href="practical-approaches.html">
                              A Framework for Prescribing
                            </a>
                          </li>
                          <li class="collapsed level-2 menu-link-2356">
                            <a href="appropriate-treatment.html">
                              Clinically Appropriate Treatment Selection
                            </a>
                          </li>
                          <li class="collapsed level-2 active-trail menu-link-2371">
                            <a href="applying-universal-precautions.html"  class="active-trail active">
                              Applying Universal Precautions When Prescribing
                            </a>
                          </li>
                          <li class="last collapsed level-2 menu-link-2396">
                            <a href="principles-in-practice.html">
                              Universal Precautions in Practice: Case Studies
                            </a>
                          </li>
                        </ul>
                      </li>
                      <li class="last expanded level-1 menu-link-2986">
                        <a title="" class="menu-dropdown-with-ul">
                          Tools and Resources
                          <span class="more-indicator">
                            »
                          </span>
                        </a>

                        <ul class="menu" style="display: none; visibility: hidden;">
                          <li class="first leaf level-2 menu-link-2421">
                            <a href="tools-and-resources.html">
                              Overview of Resources
                            </a>
                          </li>
                          <li class="leaf level-2 menu-link-2426">
                            <a href="patient-assessment-tools.html">
                              Patient Assessment Tools
                            </a>
                          </li>
                          <li class="leaf level-2 menu-link-2431">
                            <a href="precautions-implementation-tool.html">
                              Universal Precautions Implementation Tool
                            </a>
                          </li>
                          <li class="leaf level-2 menu-link-2436">
                            <a href="guidelines.html">
                              Guidelines and Templates
                            </a>
                          </li>
                          <li class="last leaf level-2 menu-link-2441">
                            <a href="glossary.html">
                              Glossary
                            </a>
                          </li>
                        </ul>
                      </li>
                    </ul>
                  </div>
                </div>
                <div class="bottom">
                  <div class="bottom-inset-1 tb-terminal">
                    <div class="bottom-inset-2 tb-terminal">
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
        <div id="content">
          <div id="sidebar-a" class="col-a sidebar left">
            <div class="block">
              <ul class="menu">
                <li class="first leaf level-1 menu-link-3076">
                  <a href="applying-universal-precautions.html" title="">
                    Applying Universal Precautions When Prescribing
                  </a>
                </li>
                <li class="leaf level-1 menu-link-3081">
                  <a href="assess-risk.html" title="" >
                    Step 1: Assess Risk
                  </a>
                </li>
                <li class="leaf active-trail level-1 menu-link-3086">
                  <a href="select-agent.html" title="" class="active-trail active">
                    Step 2: Select Agent
                  </a>
                </li>
                <li class="leaf level-1 menu-link-3091">
                  <a href="dialogue-with-patient.html" title="">
                    Step 3: Dialogue With Patient
                  </a>
                </li>
                <li class="last leaf level-1 menu-link-3096">
                  <a href="monitor-treatment.html" title="">
                    Step 4: Monitor Treatment
                  </a>
                </li>
              </ul>
            </div>
            <div>
              <div class="left-panel flw">
                <img src="img/left-hand-art4.png">
              </div>
            </div>
          </div>
          <div id="main" class="col-c">
            <div id="custom-accordion">
              <h3 class="select_agent">
                Step 2: Select Agent
              </h3>
              <div>
                <div class="acc_wrapper clearfix">
                  <div class="acc_cont clearfix">
                    <div class="acc_text">
                      <h1>
                        Universal Precautions, Step 2: Select Agent
                      </h1>
                      <p>
                        If your clinical and risk assessment of the patient with chronic pain indicates that prescription opioid therapy is appropriate, the next step is to select a specific opioid agent. Numerous
                        <a href="guidelines.html" id="treatment_guidelines_Step2">
                          treatment guidelines
                        </a>
                        exist to help guide the selection of appropriate opioid therapy for patients with chronic pain.
                        <sup>
                          <a class="accordin-scroll" href="#1_ref_1">
                            1
                          </a>
                          -
                          <a class="accordin-scroll" href="#1_ref_5">
                            5
                          </a>
                        </sup>
                      </p>
                      <p>
                        Factors to consider when selecting an opioid agent and dosage include, but are not limited to, the patient&rsquo;s general condition, medical status, and prior experience with opioids, including whether he or she is opioid tolerant.
                        <sup>
                          <a class="accordin-scroll" href="#1_ref_1">
                            1
                          </a>
                          ,
                          <a class="accordin-scroll" href="#1_ref_6">
                            6
                          </a>
                        </sup>
                        Patients who are opioid tolerant are those receiving, for 1 week or longer, at least 60 mg/day oral morphine, 25 mcg/hour transdermal fentanyl, 30 mg/day oral oxycodone, 8 mg/day oral hydromorphone, 25 mg/day oral oxymorphone, or an equianalgesic dose of another opioid.
                        <sup>
                          <a class="accordin-scroll" href="#1_ref_6">
                            6
                          </a>
                        </sup>
                      </p>
                      <p>
                        Another emerging consideration is opioid
                        <a class="inline" href="#inline_content" id="pharmacogenetics_Step2">
                          pharmacogenetics
                        </a>
                        .
                      </p>
                      <div class="ltbox-cont clearfix">
                        <div class="ltbox" id="inline_content">
                          <div class="lt-content">
                            <h3>
                              Pharmacogenetics
                            </h3>
                            <p>
                              The rapidly progressing field of pharmacogenetics promises to contribute to our understanding of the variation in patient response to mu-opioid analgesics. For example, patients who have low or high expression of enzymes that are essential to the metabolism of specific opioid agents may experience poor efficacy or exaggerated medication effects, respectively.
                              <sup>
                                <a href="#lt-one" onclick="scrollToLink('#lt-one');">
                                  1
                                </a>
                                ,
                                <a href="#lt-two">
                                  2
                                </a>
                              </sup>
                              Pharmacogenetics soon may be applied in clinical practice to better predict which opioid agent may be best for an individual patient. For now, careful titration of treatment to patient response is key.
                              <sup>
                                <a href="#lt-one">
                                  1
                                </a>
                              </sup>
                            </p>
                          </div>
                          <div class="references">
                            <p>
                              References
                            </p>
                            <ol>
                              <li>
                                <a id="lt-one" name="lt-one">
                                </a>
                                Argoff CE. Clinical implications of opioid pharmacogenetics [review].
                                <em>
                                  Clin J Pain.
                                </em>
                                2010;26(suppl 10):S16-S20. PMID:
                                <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20026961" target="_blank">
                                  20026961
                                </a>
                              </li>
                              <li>
                                <a id="lt-two" name="lt-two">
                                </a>
                                Vuilleumier PH, Stamer UM, Landau R. Pharmacogenomic considerations in opioid analgesia [review].
                                <em>
                                  Pharmgenomics Pers Med.
                                </em>
                                2012;5:73-87. PMID:
                                <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23226064" target="_blank">
                                  23226064
                                </a>
                              </li>
                            </ol>
                          </div>
                        </div>
                      </div>
                      <p>
                        After deciding on an opioid agent, you may wish to consider prescribing an abuse-deterrent opioid, if one is available.
                        <sup>
                          <a class="accordin-scroll" href="#1_ref_7">
                            7
                          </a>
                          ,
                          <a class="accordin-scroll" href="#1_ref_8">
                            8
                          </a>
                        </sup>
                        Abuse-deterrent opioids are opioids that have been given FDA approval for demonstrating an ability to reduce abuse: (a) by making manipulation of the opioid&mdash;by crushing, chewing, dissolving, or extracting&mdash;more difficult, and/or (b) by making the effect of the manipulated opioid less attractive or rewarding. These products do not address the problem of oral overconsumption.
                        <sup>
                          <a class="accordin-scroll" href="#1_ref_9">
                            9
                          </a>
                        </sup>
                        Select a tab below for more information about methods and routes of prescription opioid abuse and the types of abuse-deterrent opioids.
                      </p>
                      <p>
                        Note that careful consideration should be given to the initial quantity of opioid medication prescribed. Patients receiving opioid therapy for the first time or being switched to a different opioid agent might require dose titration within the first 2 to 4 weeks. The follow-up interval should be considered when deciding on the initial quantity of medication. Be sure you are familiar with any state regulations concerning maximum quantities for opioid prescriptions; numerous states restrict these prescriptions to a 30-day supply.
                        <sup>
                          <a class="accordin-scroll" href="#1_ref_10">
                            10
                          </a>
                        </sup>
                      </p>
                      <div class="note">
                        <p>
                          Abuse-deterrent formulations do not address oral overconsumption of prescription opioids, which is the most common form of prescription opioid abuse.
                          <sup>
                            <a class="accordin-scroll" href="#1_ref_9">
                              9
                            </a>
                          </sup>
                          There are limited data available to assess the impact of abuse-deterrent formulations on drug abuse, misuse, and diversion, and further studies are needed.
                          <sup>
                            <a class="accordin-scroll" href="#1_ref_7">
                              7
                            </a>
                            ,
                            <a class="accordin-scroll" href="#1_ref_11">
                              11
                            </a>
                          </sup>
                        </p>
                      </div>
                      <p>
                        As you do with any medication, consult the product labeling for the prescription opioid agent you have selected.
                      </p>
                      <div class="note">
                        <p>
                          Select a tab below for more information about agent selection.
                        </p>
                      </div>
                      <div class="next">
                        <div class="next_2 fl n-width2">
                          Step 3:
                          <a href="dialogue-with-patient" id="Dialogue_With_Patient_Step2">
                            Dialogue With Patient
                          </a>
                        </div>
                      </div>
                    </div>
                    <div class="references">
                      <p>
                        References
                      </p>
                      <ol>
                        <li>
                          <a id="1_ref_1" name="one">
                          </a>
                          Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society&ndash;American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.
                          <em>
                            J Pain
                          </em>
                          . 2009;10(2):113-130. PMID:
                          <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19187889" target="_blank">
                            19187889
                          </a>
                        </li>
                        <li>
                          <a id="1_ref_2" name="two">
                          </a>
                          US Department of Veterans Affairs, US Department of Defense.
                          <em>
                            VA/DoD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain
                          </em>
                          . Version 2.0. Washington, DC: US Dept of Veterans Affairs, US Dept of Defense; 2010. http://www.va.gov/PAINMANAGEMENT/docs/CPG_opioidtherapy_summary.pdf. Accessed May 20, 2014.
                        </li>
                        <li>
                          <a id="1_ref_3" name="three">
                          </a>
                          Washington State Agency Medical Directors&rsquo; Group (AMDG).
                          <em>
                            Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain: An Educational Aid to Improve Care and Safety With Opioid Therapy
                          </em>
                          . 2010 Update. Olympia, WA: Washington State Agency Medical Directors Group; 2010. http://www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf. Accessed May 20, 2014.
                        </li>
                        <li>
                          <a id="1_ref_4" name="four">
                          </a>
                          Manchikanti L, Abdi S, Atluri S, et al; American Society of Interventional Pain Physicians. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2&mdash;guidance.
                          <em>
                            Pain Physician
                          </em>
                          . 2012;15(3 suppl):S67-S116. PMID:
                          <a href="http://www.ncbi.nlm.nih.gov/pubmed/22786449" target="_blank">
                            22786449
                          </a>
                        </li>
                        <li>
                          <a id="1_ref_5" name="five">
                          </a>
                          Utah Department of Health.
                          <em>
                            Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain
                          </em>
                          . Salt Lake City, UT: Utah Dept of Health; 2009. http://www.dopl.utah.gov/licensing/forms/OpioidGuidlines.pdf. Accessed May 20, 2014.
                        </li>
                        <li>
                          <a id="1_ref_6" name="six">
                          </a>
                          US Food and Drug Administration. ER/LA Opioid Analgesic Class Labeling Changes and Postmarket Requirements. Letter to ER/LA opioid application holders.
                          <a href="http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM367697.pdf" target="_blank">
                            http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM367697.pdf
                          </a>
                          . Accessed May 20, 2014.
                        </li>
                        <li>
                          <a id="1_ref_7" name="seven">
                          </a>
                          Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions.
                          <em>
                            Mayo Clin Proc
                          </em>
                          . 2009;84(7):593-601. PMID:
                          <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19567713" target="_blank">
                            19567713
                          </a>
                        </li>
                        <li>
                          <a id="1_ref_8" name="eight">
                          </a>
                          Webster LR, Fine PG. Approaches to improve pain relief while minimizing opioid abuse liability.
                          <em>
                            J Pain
                          </em>
                          . 2010;11(7):602-611. PMID:
                          <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20444651" target="_blank">
                            20444651
                          </a>
                        </li>
                        <li>
                          <a id="1_ref_9" name="nine">
                          </a>
                          US Food and Drug Administration.
                          <em>
                            Guidance for Industry: Abuse-Deterrent Opioids&mdash;Evaluation and Labeling
                          </em>
                          [draft guidance]. Silver Spring, MD: FDA; 2013.
                        </li>
                        <li>
                          <a id="1_ref_10" name="ten">
                          </a>
                          Medscape Web site. State-by-State Opioid Prescribing Policies. http://www.medscape.com/resource/opioid/opioid-policies. Accessed May 20, 2014.
                        </li>
                        <li>
                          <a id="1_ref_11" name="eleven">
                          </a>
                          Stanos S. Continuing evolution of opioid use in primary care practice: implications of emerging technologies.
                          <em>
                            Curr Med Res Opin
                          </em>
                          . 2012;28(9):1505-1516. PMID:
                          <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22937723" target="_blank">
                            22937723
                          </a>
                        </li>
                      </ol>
                    </div>
                  </div>
                </div>
                <div id="pharmacogenetics">
                  <p>
                    <strong>
                      Pharmacogenetics
                    </strong>
                  </p>
                  <p>
                    The rapidly progressing field of pharmacogenetics promises to contribute to our understanding of the variation in patient response to mu-opioid analgesics. For example, patients who have low or high expression of enzymes that are essential to the metabolism of specific opioid agents may experience poor efficacy or exaggerated medication effects, respectively.
                    <sup>
                      <a href="#one">
                        1
                      </a>
                      ,
                      <a href="#two">
                        2
                      </a>
                    </sup>
                    Pharmacogenetics soon may be applied in clinical practice to better predict which opioid agent may be best for an individual patient. For now, careful titration of treatment to patient response is key.
                    <sup>
                      <a href="#one">
                        1
                      </a>
                    </sup>
                  </p>
                  <div class="references">
                    <p>
                      References
                    </p>
                    <ol>
                      <li>
                        <a id="one" name="one">
                        </a>
                        Argoff CE. Clinical implications of opioid pharmacogenetics [review].
                        <em>
                          Clin J Pain
                        </em>
                        . 2010;26(suppl 10):S16-S20. PMID:
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20026961" target="_blank">
                          20026961
                        </a>
                      </li>
                      <li>
                        <a id="two" name="two">
                        </a>
                        Vuilleumier PH, Stamer UM, Landau R. Pharmacogenomic considerations in opioid analgesia [review].
                        <em>
                          Pharmgenomics Pers Med
                        </em>
                        . 2012;5:73-87. PMID:
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23226064" target="_blank">
                          23226064
                        </a>
                      </li>
                    </ol>
                  </div>
                </div>
              </div>
              <h3 class="methods_routes">
                Methods and Routes of Prescription Opioid Abuse
              </h3>
              <div>
                <div class="acc_wrapper clearfix">
                  <div class="acc_cont clearfix">
                    <h1>
                      Universal Precautions, Step 2: Select Agent
                    </h1>
                    <div class="acc_img fl">
                      <img alt="" src="img/201403_methods-of-abuse_0.png" />
                    </div>
                    <div class="after-img-txt">
                      Adapted from Katz N, Dart RC, Bailey E, Trudeau J, Osgood E, Paillard F. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions.
                      <em>
                        Am J Drug Alcohol Abuse.
                      </em>
                      2011;37(4):205-217. PMID:
                      <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21517709" target="_blank">
                        21517709
                      </a>
                    </div>
                    <div class="acc_text">
                      <p>
                        When selecting an opioid agent, consideration should be given to the potential methods and routes of prescription opioid abuse.
                        <sup>
                          <a class="accordin-scroll" href="#2_ref_1">
                            1
                          </a>
                        </sup>
                        Although a variety of methods and routes of abuse are well-documented, oral ingestion of the intact drug form is the most common method of abuse overall.
                        <sup>
                          <a class="accordin-scroll" href="#2_ref_2">
                            2
                          </a>
                        </sup>
                        In one large-scale survey of patients entering addiction treatment programs, 72% of users of a common prescription opioid stated that they took the medication orally (vs by inhalation or injection).
                        <sup>
                          <a class="accordin-scroll" href="#2_ref_3">
                            3
                          </a>
                        </sup>
                      </p>
                      <p>
                        The most common methods of abuse may vary among specific opioid medications, however.
                        <sup>
                          <a class="accordin-scroll" href="#2_ref_4">
                            4
                          </a>
                        </sup>
                        Extended-release (ER) formulations of prescription opioids, because of their relatively high opioid content compared with immediate-release (IR) formulations, are prone to tampering for abuse by nonoral routes.
                        <sup>
                          <a class="accordin-scroll" href="#2_ref_1">
                            1
                          </a>
                          ,
                          <a class="accordin-scroll" href="#2_ref_5">
                            5
                          </a>
                        </sup>
                        Most
                        <a href="javascript:void(0);" id="abuse_deterrent_step2">
                          abuse-deterrent
                        </a>
                        opioids have been designed to make product manipulation more difficult.
                        <sup>
                          <a class="accordin-scroll" href="#2_ref_2">
                            2
                          </a>
                        </sup>
                      </p>
                      <div class="next">
                        <div class="next_2 fl n-width2">
                          Step 3:
                          <a href="dialogue-with-patient.html" id="Dialogue_With_Patient_Step2_3">
                            Dialogue With Patient
                          </a>
                        </div>
                      </div>
                    </div>
                    <div class="references">
                      <p>
                        References
                      </p>
                      <ol>
                        <li>
                          <a id="2_ref_1" name="one">
                          </a>
                          Katz N, Dart RC, Bailey E, Trudeau J, Osgood E, Paillard F. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions.
                          <em>
                            Am J Drug Alcohol Abuse
                          </em>
                          . 2011;37:205-217. PMID:
                          <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21517709" target="_blank">
                            21517709
                          </a>
                        </li>
                        <li>
                          <a id="2_ref_2" name="two">
                          </a>
                          US Food and Drug Administration.
                          <em>
                            Guidance for Industry: Abuse-Deterrent Opioids&mdash;Evaluation and Labeling
                          </em>
                          [draft guidance]. Silver Spring, MD: FDA; 2013.
                        </li>
                        <li>
                          <a id="2_ref_3" name="three">
                          </a>
                          Carise D, Dugosh KL, McLellan AT, Camilleri A, Woody GE, Lynch KG. Prescription OxyContin abuse among patients entering addiction treatment.
                          <em>
                            Am J Psychiatry
                          </em>
                          . 2007;164(11):1750-1756.
                        </li>
                        <li>
                          <a id="2_ref_4" name="four">
                          </a>
                          Butler SF, Black RA, Cassidy TA, Dailey TM, Budman SH. Abuse risks and routes of administration of different prescription opioid compounds and formulations.
                          <em>
                            Harm Reduct J
                          </em>
                          . 2011;8:29. PMID:
                          <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22011626" target="_blank">
                            22011626
                          </a>
                        </li>
                        <li>
                          <a id="2_ref_5" name="five">
                          </a>
                          Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.
                          <em>
                            J Pain
                          </em>
                          . 2013;14(4):351-358.
                        </li>
                      </ol>
                    </div>
                  </div>
                </div>
              </div>
              <h3 class="last-tab categories_opioids">
                Categories of Abuse-deterrent Opioids
              </h3>
              <div>
                <div class="acc_wrapper clearfix">
                  <div class="acc_cont clearfix">
                    <h1>
                      Universal Precautions, Step 2: Select Agent
                    </h1>
                    <div class="sl-chart-main">
                      <h3>
                        Abuse-Deterrent Opioid Categories
                        <sup>
                          <a class="accordin-scroll" href="#3_ref_1" style="color:#A9AE00">
                            1
                          </a>
                        </sup>
                      </h3>
                      <div class="select-chart-top">
                        <div class="chart-text1">
                          Category
                        </div>
                        <div class="chart-divider">
                          &nbsp;
                        </div>
                        <div class="chart-text2">
                          Description
                        </div>
                      </div>
                      <div class="select-chart-mid">
                        <table border="0" cellpadding="0" cellspacing="0" class="chart-tbl">
                          <tbody>
                            <tr>
                              <td class="chart-td1">
                                Physical/chemical barrier
                              </td>
                              <td class="chart-td2">
                                Prevent/deter manipulation and tampering
                              </td>
                            </tr>
                            <tr>
                              <td class="chart-td1">
                                Agonist/antagonist combination
                              </td>
                              <td class="chart-td2">
                                Antagonist can interfere with, reduce, or defeat euphoria associated with abuse
                              </td>
                            </tr>
                            <tr>
                              <td class="chart-td1">
                                Aversion
                              </td>
                              <td class="chart-td2">
                                Substances can be combined to produce unpleasant effect if dosage manipulated or higher-than-directed dose used
                              </td>
                            </tr>
                            <tr>
                              <td class="chart-td1">
                                Delivery system
                              </td>
                              <td class="chart-td2">
                                Drug-release design or method of drug delivery (eg, depot injection) offers resistance to abuse
                              </td>
                            </tr>
                            <tr>
                              <td class="chart-td1">
                                Prodrug
                              </td>
                              <td class="chart-td2">
                                Lacks opioid activity until converted to active drug in GI tract
                              </td>
                            </tr>
                            <tr>
                              <td class="chart-td1">
                                Combination
                              </td>
                              <td class="chart-td2">
                                Two or more of the above methods
                              </td>
                            </tr>
                          </tbody>
                        </table>
                      </div>
                      <div class="univ-bottom">
                        Adapted from US Food and Drug Administration.
                        <em>
                          Guidance for Industry: Abuse-Deterrent Opioids&mdash;Evaluation and Labeling
                        </em>
                        [draft guidance]. Silver Spring, MD: FDA; 2013.
                      </div>
                    </div>
                    <div class="acc_text">
                      <p>
                        Abuse-deterrent opioids may be grouped into several distinct categories, based on the potential mechanism(s) by which they are designed to help to deter abuse.
                        <sup>
                          <a class="accordin-scroll" href="#3_ref_1">
                            1
                          </a>
                          -
                          <a class="accordin-scroll" href="#3_ref_3">
                            3
                          </a>
                        </sup>
                        The categories shown here represent
                        <em>
                          potential
                        </em>
                        types of abuse-deterrent opioids.
                      </p>
                      <div>
                        <div class="parent-note">
                          <div class="note">
                            <p>
                              Abuse-deterrent formulations do not address oral overconsumption of prescription opioids, which is the most common form of prescription opioid abuse.
                              <sup>
                                <a class="accordin-scroll" href="#3_ref_1">
                                  1
                                </a>
                              </sup>
                              There are limited data available to assess the impact of abuse-deterrent formulations on drug abuse, misuse, and diversion, and further studies are needed.
                              <sup>
                                <a class="accordin-scroll" href="#3_ref_4">
                                  4
                                </a>
                                ,
                                <a class="accordin-scroll" href="#3_ref_5">
                                  5
                                </a>
                              </sup>
                            </p>
                          </div>
                        </div>
                      </div>
                      <div class="next">
                        <div class="next_2 fl n-width2">
                          Step 3:
                          <a href="dialogue-with-patient.html" id="Dialogue_With_Patient_step2_accod3">
                            Dialogue With Patient
                          </a>
                        </div>
                      </div>
                    </div>
                    <div class="references">
                      <p>
                        References
                      </p>
                      <ol>
                        <li>
                          <a id="3_ref_1" name="one">
                          </a>
                          US Food and Drug Administration.
                          <em>
                            Guidance for Industry: Abuse-Deterrent Opioids&mdash;Evaluation and Labeling
                          </em>
                          [draft guidance]. Silver Spring, MD: FDA; 2013.
                        </li>
                        <li>
                          <a id="3_ref_2" name="two">
                          </a>
                          Romach MK, Schoedel KA, Sellers EM. Update on tamper-resistant drug formulations.
                          <em>
                            Drug Alcohol Depend
                          </em>
                          . 2013;130(1-3):13-23. PMID:
                          <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23415386" target="_blank">
                            23415386
                          </a>
                        </li>
                        <li>
                          <a id="3_ref_3" name="three">
                          </a>
                          Stanos SP, Bruckenthal P, Barkin RL. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering.
                          <em>
                            Mayo Clin Proc
                          </em>
                          . 2012;87(7):683-694. PMID:
                          <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22766088" target="_blank">
                            22766088
                          </a>
                        </li>
                        <li>
                          <a id="3_ref_4" name="four">
                          </a>
                          Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions.
                          <em>
                            Mayo Clin Proc
                          </em>
                          . 2009;84(7):593-601. PMID:
                          <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19567713" target="_blank">
                            19567713
                          </a>
                        </li>
                        <li>
                          <a id="3_ref_5" name="five">
                          </a>
                          Stanos S. Continuing evolution of opioid use in primary care practice: implications of emerging technologies.
                          <em>
                            Curr Med Res Opin
                          </em>
                          . 2012;28(9):1505-1516. PMID:
                          <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22937723" target="_blank">
                            22937723
                          </a>
                        </li>
                      </ol>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
        <div id="footer">
          <div class="ft clearfix">
            <div class="ft-wr clearfix">
              <span>
                Any product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.
              </span>
            </div>

            <div class="ft-wr clearfix">
              <div class="pf-logo fl">
                <img alt="Pfizer Logo" height="35" src="img/pfizer-logo.png" width="56">
              </div>

              <p class="fl">
                Copyright © 2014 Pfizer Inc. All rights reserved. EMB695705-01
              </p>
            </div>
          </div>
        </div>
      </div>
    </div>
  </body>

</html>
